|
THE PHARMA REVIEW
(MAY 2010) |
Romidepsin: A Histone
Deacetylase Inhibitor for the Treatment of Cutaneous T
Cell Lymohoma
|
|
Seema Jain, Nidhi B.
Agarwal |
|
Abstract
Romidepsin (depsipeptide, FK228) is a new anticancer
drug approved for the treatment of cutaneous T cell
lymphoma (CTCL). It is a bicyclic peptide isolated from
Chromobacterium violaceum bacteria. It acts by
inhibiting histone deacetylase enzymes which regulate
transcription process and other cellular processes in
the cells. It is indicated in dose of 14 mg/m², infused
intravenously over a 4-hour period on day 1, day 8 and
day 15 of a 28-day cycle of treatment in those patients
who have received at least one prior systemic therapy
for CTCL. In clinical trials the most commonly reported
adverse effects with the use of romidepsin are
gastrointestinal disorders like nausea, vomiting,
diarrhea, loss of appetite and tiredness. This drug is
currently in various phase of clinical trials for the
treatment of other malignancies like multiple myeloma,
head and neck cancer and lung cancer etc., which might
indicate its potential use in these malignancies in
future.
For full text of this article contact the publisher on
info@kppub.com
|
|
Go to Content Index Page
|
|
The above content is an
abstract only. For the full Article please contact:
KONGPOSH Publications Pvt. Ltd.
ICS House, C-19, Commercial Complex, SDA, Opp. IIT Gate,
New Delhi, India -110016
Tel.: 26855839, 20057149, Fax: 91-11-26855876
Email:
info@kppub.com /
fpc@vsnl.com, Website:
http://www.kppub.com |
|
|
|
